These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Li Y; Chan SC; Brand LJ; Hwang TH; Silverstein KA; Dehm SM Cancer Res; 2013 Jan; 73(2):483-9. PubMed ID: 23117885 [TBL] [Abstract][Full Text] [Related]
88. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Gaddipati JP; McLeod DG; Heidenberg HB; Sesterhenn IA; Finger MJ; Moul JW; Srivastava S Cancer Res; 1994 Jun; 54(11):2861-4. PubMed ID: 8187068 [TBL] [Abstract][Full Text] [Related]
89. Androgen receptor gene mutations in human prostate cancer. Suzuki H; Sato N; Watabe Y; Masai M; Seino S; Shimazaki J J Steroid Biochem Mol Biol; 1993 Dec; 46(6):759-65. PubMed ID: 8274409 [TBL] [Abstract][Full Text] [Related]
90. Proteomic-coupled-network analysis of T877A-androgen receptor interactomes can predict clinical prostate cancer outcomes between White (non-Hispanic) and African-American groups. Zaman N; Giannopoulos PN; Chowdhury S; Bonneil E; Thibault P; Wang E; Trifiro M; Paliouras M PLoS One; 2014; 9(11):e113190. PubMed ID: 25409505 [TBL] [Abstract][Full Text] [Related]
91. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. Isikbay M; Otto K; Kregel S; Kach J; Cai Y; Vander Griend DJ; Conzen SD; Szmulewitz RZ Horm Cancer; 2014 Apr; 5(2):72-89. PubMed ID: 24615402 [TBL] [Abstract][Full Text] [Related]
92. Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide. Rathkopf DE; Smith MR; Ryan CJ; Berry WR; Shore ND; Liu G; Higano CS; Alumkal JJ; Hauke R; Tutrone RF; Saleh M; Chow Maneval E; Thomas S; Ricci DS; Yu MK; de Boer CJ; Trinh A; Kheoh T; Bandekar R; Scher HI; Antonarakis ES Ann Oncol; 2017 Sep; 28(9):2264-2271. PubMed ID: 28633425 [TBL] [Abstract][Full Text] [Related]
93. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Chen EJ; Sowalsky AG; Gao S; Cai C; Voznesensky O; Schaefer R; Loda M; True LD; Ye H; Troncoso P; Lis RL; Kantoff PW; Montgomery RB; Nelson PS; Bubley GJ; Balk SP; Taplin ME Clin Cancer Res; 2015 Mar; 21(6):1273-80. PubMed ID: 25320358 [TBL] [Abstract][Full Text] [Related]
97. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Visakorpi T; Hyytinen E; Koivisto P; Tanner M; Keinänen R; Palmberg C; Palotie A; Tammela T; Isola J; Kallioniemi OP Nat Genet; 1995 Apr; 9(4):401-6. PubMed ID: 7795646 [TBL] [Abstract][Full Text] [Related]
98. Mutated human androgen receptor gene detected in a prostatic cancer patient is also activated by estradiol. Elo JP; Kvist L; Leinonen K; Isomaa V; Henttu P; Lukkarinen O; Vihko P J Clin Endocrinol Metab; 1995 Dec; 80(12):3494-500. PubMed ID: 8530589 [TBL] [Abstract][Full Text] [Related]
99. Androgen receptor defects: historical, clinical, and molecular perspectives. Quigley CA; De Bellis A; Marschke KB; el-Awady MK; Wilson EM; French FS Endocr Rev; 1995 Jun; 16(3):271-321. PubMed ID: 7671849 [No Abstract] [Full Text] [Related]
100. CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Nagabhushan M; Miller CM; Pretlow TP; Giaconia JM; Edgehouse NL; Schwartz S; Kung HJ; de Vere White RW; Gumerlock PH; Resnick MI; Amini SB; Pretlow TG Cancer Res; 1996 Jul; 56(13):3042-6. PubMed ID: 8674060 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]